

# Single Agent Carboplatin for Seminoma

## Indication

Stage I seminoma as alternative to prophylactic radiotherapy

## Regimen details

Carboplatin AUC7 in 500ml 5% Dextrose over 1 hour

## Cycle frequency

N/A

## Number of cycles

1 cycle only

## Emetogenicity

Moderately emetogenic

## Additional supportive medication

### Investigations – pre first cycle

CT thorax/abdo/pelvis

FBC

U&E

LFT

AFP, HCG, LDH

Calculated creatinine clearance

### Investigations –pre subsequent cycles

N/A

### Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant.

Investigation	Limit
Neutrophil count	$\geq 1.5 \times 10^9/L$
Platelet count	$\geq 100 \times 10^9/L$
Creatinine clearance	$\geq 40\text{mL}/\text{min}$
Bilirubin	$\leq 1.5 \times \text{ULN}$
AST	$< 1.5 \times \text{ULN}$

## Dose modifications

N/A

**Adverse effects** - for full details consult product literature/ reference texts

Bone marrow suppression

Nausea and vomiting

Alopecia (very occasionally)

Need for contraception during treatment

---

**THIS PROTOCOL HAS BEEN DIRECTED BY DR BIRTLE, DESIGNATED LEAD CLINICIAN FOR GERM CELL TUMOURS**

**RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE**

Date: July 2020

Review: July 2022

VERSION: 9

---